Menu
Menu
AlzeCure Pharma
Developing a broad portfolio of symptomatic, disease-modifying and preventive drugs for Alzheimer’s, pain and other severe illnesses.
- Healthtech, Pharma
- IPO
Location
Stockholm, Sweden
Revenue size
0 (in 2023)
Year founded
2016
Funding raised
110 million SEK, before going public
Founders
Johan Sandin, Gunnar Nordvall, Pontus Forsell, Johan Lundkvist and Magnus Halldin
Most relevant investors
Dr. Jan Lundberg, former Eli Lilly and AstraZeneca
Team size
11 on core team
Problem
Patients need effective treatment options for Alzheimer’s disease, traumatic brain injury, sleep apnea, Parkinson’s disease, arthritis, and other chronic and acute afflictions.
SOLUTION
AlzeCure Pharma is developing a broad portfolio of symptomatic, disease-modifying and preventive drugs for Alzheimer’s, pain and other severe illnesses through work based on the following four guidelines: - The right patient: Focusing on genetically, clinically and pathologically defined diseases to increase the ability of clinical effect - The right mechanism: The treatment acts on genetically associated signaling pathways in Alzheimer’s disease and other indications. - The right clinical testing: The clinical studies are based on validated biomarkers and preclinical methods with good translation to humans. - The right treatment: Small-molecule drugs that penetrate the blood brain barrier (BBB) and which are designed for safe, efficacious long-term treatment.
KEY CUSTOMERS AND INTERNATIONAL PRESENCE
Pharma— works primarily in research and drug development, so key customers will be pharma companies and hospitals
Team
The group has more than 100 years’ collective experience from research and development at several different pharmaceutical companies, including AstraZeneca, Merck Frosst and Orexo. They have published several studies in high ranking scientific journals and have contributed to several drug candidates that have been tested in clinical trials and also to the introduction of drugs to the market. The management team has a long experience in drug discovery and development within the Alzheimer field and a large network of collaborators.
Unique selling point
AlzeCure® works with several research platforms: NeuroRestore® and Alzstatin® – with a focus on Alzheimer’s disease, where the leading candidate ACD856 is in clinical development phase. Painless – focuses on pain treatment and contains two projects: ACD440 in clinical development phase and TrkA-NAM in research phase.